A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
Phase 1
Terminated
- Conditions
- HIV Infections
- Interventions
- Drug: GSK3640254 TabletDrug: GSK3640254 Capsule
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 16
- Registration Number
- NCT04128293
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)
Phase 3
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: DTG/3TC FDCDrug: CAR
- First Posted Date
- 2019-07-16
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 493
- Registration Number
- NCT04021290
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 774
- Registration Number
- NCT04019873
- Locations
- 🇪🇸
GSK Investigational Site, Barcelona, Spain
Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)
Phase 3
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: CAB LA+RPV LA
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 115
- Registration Number
- NCT04001803
- Locations
- 🇺🇸
GSK Investigational Site, Dallas, Texas, United States
Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive
- First Posted Date
- 2019-06-13
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 23
- Registration Number
- NCT03984825
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study
- First Posted Date
- 2019-06-13
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 24
- Registration Number
- NCT03984812
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2019-06-13
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 16
- Registration Number
- NCT03984838
- Locations
- 🇺🇸
GSK Investigational Site, Glendale, California, United States
Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 131
- Registration Number
- NCT03945981
- Locations
- 🇺🇸
GSK Investigational Site, Dallas, Texas, United States
Dolutegravir Pediatric Liquid Formulation Study
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 22
- Registration Number
- NCT03921723
- Locations
- 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom
Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 16
- Registration Number
- NCT03836729
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath